EP3938365A4 - Compositions and methods for treating androgen receptor positive forms of cancer - Google Patents

Compositions and methods for treating androgen receptor positive forms of cancer Download PDF

Info

Publication number
EP3938365A4
EP3938365A4 EP20774663.7A EP20774663A EP3938365A4 EP 3938365 A4 EP3938365 A4 EP 3938365A4 EP 20774663 A EP20774663 A EP 20774663A EP 3938365 A4 EP3938365 A4 EP 3938365A4
Authority
EP
European Patent Office
Prior art keywords
cancer
compositions
methods
androgen receptor
receptor positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20774663.7A
Other languages
German (de)
French (fr)
Other versions
EP3938365A1 (en
Inventor
Maureen Caligiuri
Anna Ericsson
Sylvie GUICHARD
Qunli Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/039936 external-priority patent/WO2020006483A1/en
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of EP3938365A1 publication Critical patent/EP3938365A1/en
Publication of EP3938365A4 publication Critical patent/EP3938365A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20774663.7A 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer Pending EP3938365A4 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962819476P 2019-03-15 2019-03-15
US201962819472P 2019-03-15 2019-03-15
US201962819487P 2019-03-15 2019-03-15
US201962819490P 2019-03-15 2019-03-15
US201962819482P 2019-03-15 2019-03-15
US201962821660P 2019-03-21 2019-03-21
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)
PCT/US2020/022823 WO2020190792A1 (en) 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer

Publications (2)

Publication Number Publication Date
EP3938365A1 EP3938365A1 (en) 2022-01-19
EP3938365A4 true EP3938365A4 (en) 2023-01-25

Family

ID=72521203

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20774663.7A Pending EP3938365A4 (en) 2019-03-15 2020-03-13 Compositions and methods for treating androgen receptor positive forms of cancer

Country Status (7)

Country Link
EP (1) EP3938365A4 (en)
CN (1) CN113784967A (en)
AU (1) AU2020241709A1 (en)
BR (1) BR112021018266A2 (en)
CA (1) CA3132995A1 (en)
MX (1) MX2021011154A (en)
WO (1) WO2020190792A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
EP2412710A1 (en) * 2009-03-27 2012-02-01 Kowa Company, Ltd. Fused piperidine compound and pharmaceutical agent comprising same
WO2016086200A1 (en) * 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2019055877A1 (en) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
WO2020006483A1 (en) * 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860695T3 (en) * 2013-11-18 2021-10-05 Forma Therapeutics Inc Tetrahydroquinoline Compositions as BET Bromodomain Inhibitors
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412710A1 (en) * 2009-03-27 2012-02-01 Kowa Company, Ltd. Fused piperidine compound and pharmaceutical agent comprising same
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2016086200A1 (en) * 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2019055877A1 (en) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
WO2020006483A1 (en) * 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020190792A1 *

Also Published As

Publication number Publication date
AU2020241709A1 (en) 2021-09-23
MX2021011154A (en) 2021-10-22
EP3938365A1 (en) 2022-01-19
BR112021018266A2 (en) 2022-02-01
CA3132995A1 (en) 2020-09-24
CN113784967A (en) 2021-12-10
WO2020190792A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
EP3947715A4 (en) Methods and compositions for treating cancer
EP3983445A4 (en) Compositions and methods for treating cancer
EP3894392A4 (en) Compositions and methods for the treatment of cancer
EP3585817A4 (en) Compositions and methods for treatment of cancer
EP3938354A4 (en) Compositions and methods for treating cancer
EP3968785A4 (en) Compositions and methods for treating cancer
EP3908601A4 (en) Methods and compositions for treating cancer
EP3965896A4 (en) Compositions and methods for treating cancer
EP3576792A4 (en) Methods, compositions, and kits for treatment of cancer
EP4055040A4 (en) Compositions and methods for treatment of cancer with lekti
EP4003351A4 (en) Methods and compositions for treating cancer
IL276203A (en) Compositions and methods of treating cancer
EP3908650A4 (en) Methods of treating cancer
IL289251A (en) Methods and compositions for treatment of pancreatic cancer
EP3773585A4 (en) Compositions and methods for treating cancer
EP3983014A4 (en) Compositions and methods for treating cancer
EP3959199A4 (en) Compositions and methods for treating ras-mutant cancers
EP3930705A4 (en) Methods and compositions for treating cancer
EP3801590A4 (en) Compositions and methods for treatment of psoriasis
EP3600329A4 (en) Compositions and method of treating cancer
EP3651795A4 (en) Compositions and methods for treatment of cancers harboring an h3k27m mutation
IL287538A (en) Compositions and methods for treatment of cancer
EP4051260A4 (en) Methods and compositions for treatment of cancer
EP3938365A4 (en) Compositions and methods for treating androgen receptor positive forms of cancer
EP4087585A4 (en) Compositions and methods for preventing recurrence of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211015

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40067268

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20221223

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20221219BHEP

Ipc: A61K 31/437 20060101ALI20221219BHEP

Ipc: C07D 471/04 20060101AFI20221219BHEP